Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Preparing for disease-modifying dementia therapies in the UK

Nature Reviews Neurology volume 20, pages 641–642 (2024)Cite this article

Subjects

Although lecanemab has been licensed for use in the UK, the systems to deliver this or similar disease-modifying therapies do not exist. These systems need to be developed urgently, but not at the expense of post-diagnostic care.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Medicines and Healthcare products Regulatory Agency. Lecanemab Licensed for Adult Patients in the Early Stages of Alzheimer’s Disease https://www.gov.uk/government/news/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease (2024).

  2. National Institute for Health and Care Excellence. Benefits of New Alzheimer’s Treatment Lecanemab are Too Small to Justify the Cost to the NHS. https://www.nice.org.uk/news/articles/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs (2024).

  3. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023).

    Article  PubMed  Google Scholar 

  4. Dobson, R. et al. Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 95, 796–803 (2024).

    Article  PubMed  Google Scholar 

  5. Anandaciva, S. How does the NHS compare to the health care systems of other countries? The King’s Fund https://www.kingsfund.org.uk/insight-and-analysis/reports/nhs-compare-health-care-systems-other-countries (2023).

  6. What are the costs of dementia diagnosis and care in the UK? Alzheimer’s Society https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-impact-numbers (2024).

  7. National Institute for Health and Care Excellence. Dementia: Assessment, Management and Support for People Living with Dementia and their Carers https://www.nice.org.uk/guidance/ng97/chapter/Recommendations (2018).

  8. Eaglestone, G. et al. Cost-effectiveness of non-pharmacological interventions for mild cognitive impairment and dementia: a systematic review of economic evaluations and a review of reviews. PharmacoEconom. Open 7, 887–914 (2023).

    Article  Google Scholar 

  9. Ballard, C. et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. PLoS Med. 15, e1002500 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Isaaq, A. et al. Cost-utility of a new psychosocial goal-setting and manualised support intervention for Independence in Dementia (NIDUS-Family) versus goal-setting and routine care: economic evaluation embedded within a randomised controlled trial. Preprint at https://www.medrxiv.org/content/10.1101/2024.08.24.24312530v1 (2024).

Download references

Author information

Authors and Affiliations

  1. Wolfson Institute of Population Health, Queen Mary University of London, London, UK

    Claudia Cooper & Charles R. Marshall

  2. Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK

    Jonathan M. Schott

  3. Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK

    Sube Banerjee

Authors
  1. Claudia Cooper
    View author publications

    Search author on:PubMed Google Scholar

  2. Charles R. Marshall
    View author publications

    Search author on:PubMed Google Scholar

  3. Jonathan M. Schott
    View author publications

    Search author on:PubMed Google Scholar

  4. Sube Banerjee
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Claudia Cooper.

Ethics declarations

Competing interests

C.R.M. has consulted for Roche and is NHS (London) Clinical Director for dementia. J.M.S. has consulted for AVID, Biogen, Eli Lilly, GE, Merck and Roche and is Chief Medical Officer for Alzheimer’s Research UK. He is supported by the NIHR UCL/H Biomedical Research Centre. S.B. has held the following positions: Non-Executive Director Somerset NHS Foundation Trust, Trustee of the Alzheimers Society, Executive Dean of the University of Plymouth, and Pro-Vice Chancellor of the University of Nottingham. He has acted as a consultant and in an educational role for Lilly and Lundbeck. C.C. is Chief investigator of the Alzheimer’s society NIDUS programme.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cooper, C., Marshall, C.R., Schott, J.M. et al. Preparing for disease-modifying dementia therapies in the UK. Nat Rev Neurol 20, 641–642 (2024). https://doi.org/10.1038/s41582-024-01022-1

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41582-024-01022-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing